CER-001

 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Apolipoprotein A-IPhospholipidsRecombinant Proteins

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression…
Importance CER-001 is a negatively charged, engineered pre-β high-density lipoprotein (HDL) mimetic containing apolipoprotein A-I… (More)
Is this relevant?
2017
2017
Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study.
BACKGROUND High-density lipoprotein (HDL) is believed to have atheroprotective properties, but an effective HDL-based therapy… (More)
Is this relevant?
2017
2017
Development of CER-001: Preclinical Dose Selection Through to Phase I Clinical Findings
BACKGROUND CER-001 comprises recombinant human apolipoprotein A-I complexed with phospholipids that mimics natural, nascent, pre… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2016
2016
HDL mimetic CER-001 targets atherosclerotic plaques in patients.
BACKGROUND AND AIMS Infusion of high-density lipoprotein (HDL) mimetics aimed at reducing atherosclerotic burden has led to… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2015
2015
Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA.
Reverse cholesterol transport (RCT) contributes to the anti-atherogenic effects of HDL. Patients with the orphan disease… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2015
2015
HDL and CER-001 Inverse-Dose Dependent Inhibition of Atherosclerotic Plaque Formation in apoE-/- Mice: Evidence of ABCA1 Down-Regulation
OBJECTIVE CER-001 is a novel engineered HDL-mimetic comprised of recombinant human apoA-I and charged phospholipids that was… (More)
  • figure 2
  • figure 3
Is this relevant?
2015
2015
The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The…
BACKGROUND Patients with homozygous familial hypercholesterolemia (HoFH) are at extremely elevated risk for early cardiovascular… (More)
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial†
AIM High-density lipoproteins (HDLs) have several potentially protective vascular effects. Most clinical studies of therapies… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2014
2014
CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice.
OBJECTIVE CER-001 is a novel engineered HDL-mimetic comprised of recombinant human apoA-I and phospholipids that was designed to… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
Effect of open-label infusion of an apolipoprotein A-I-containing particle ( CER-001 ) on reverse cholesterol transport and artery wall thickness in patients with familial hypo-alphalipoproteinemia
Background Reverse cholesterol transport (RCT) contributes to the anti-atherogenic effects of High-density lipoprotein (HDL… (More)
  • figure 2
  • figure 3
  • figure 4
Is this relevant?